文献速递造血干细胞移植与细胞治疗MDS 与骨髓增殖性肿瘤

供者类型与骨髓纤维化移植结局:一项CIBMTR研究

Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study.
PubMed 文献 · Blood Adv · 2024-01-01

该研究利用CIBMTR登记数据评估供者类型对骨髓纤维化造血细胞移植结局的影响,纳入2013至2019年移植的1597例患者。在1032例接受外周血移植物治疗慢性期骨髓纤维化的合格患者中,匹配同胞供者移植前3个月总生存优于单倍体、匹配无关及错配无关供者,但3个月后各供者类型间无显著差异。

要点

  • 匹配同胞供者移植前3个月总生存优于其他供者类型,与较低植入失败率一致。
  • 单倍体、匹配无关及错配无关供者移植前3个月总生存无显著差异。
  • 移植后3个月后,供者类型与总生存、复发、无病生存无显著差异。

核心结论

  • 匹配同胞供者移植虽在早期总生存上占优,但单倍体与匹配无关供者移植结局无显著差异。
  • 作者认为,这些结果确立了单倍体移植联合移植后环磷酰胺是骨髓纤维化的可行选择,尤其适用于供者登记库中代表性不足的少数族裔。

研究设计与样本

  • 研究利用国际血液与骨髓移植研究中心(CIBMTR)登记数据,纳入2013至2019年进行的1597例骨髓纤维化造血细胞移植。
  • 研究合格患者为1032例接受外周血移植物治疗慢性期骨髓纤维化的患者。

主要发现

  • 全部1597例患者中,单倍体供者使用比例从2013年的3%上升至2019年的19%。
  • 1032例合格患者中,单倍体移植受者38%为非白人/高加索人。
  • 匹配同胞供者移植前3个月总生存优于单倍体(HR 5.80,95%CI 2.52-13.35)、匹配无关(HR 4.50,95%CI 2.24-9.03)及错配无关供者(HR 5.13,95%CI 1.44-18.31),P < .001。
  • 匹配同胞供者植入失败率较低:单倍体HR 6.11(95%CI 2.98-12.54),匹配无关HR 2.33(95%CI 1.20-4.51),错配无关HR 1.82(95%CI 0.58-5.72)。
  • 单倍体、匹配无关及错配无关供者移植前3个月总生存无显著差异;移植后3个月后,供者类型与总生存、复发、无病生存无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We evaluate the impact of donor types on outcomes of hematopoietic cell transplantation (HCT) in myelofibrosis, using the Center for International Blood and Marrow Transplant Research registry data for HCTs done between 2013 and 2019. In all 1597 patients, the use of haploidentical donors increased from 3% in 2013 to 19% in 2019. In study-eligible 1032 patients who received peripheral blood grafts for chronic-phase myelofibrosis, 38% of recipients of haploidentical HCT were non-White/Caucasian. Matched sibling donor (MSD)-HCTs were associated with superior overall survival (OS) in the first 3 months (haploidentical hazard ratio [HR], 5.80 [95% confidence interval (CI), 2.52-13.35]; matched unrelated (MUD) HR, 4.50 [95% CI, 2.24-9.03]; mismatched unrelated HR, 5.13 [95% CI, 1.44-18.31]; P < .001). This difference in OS aligns with lower graft failure with MSD (haploidentical HR, 6.11 [95% CI, 2.98-12.54]; matched unrelated HR, 2.33 [95% CI, 1.20-4.51]; mismatched unrelated HR, 1.82 [95% CI, 0.58-5.72]). There was no significant difference in OS among haploidentical, MUD, and mismatched unrelated donor HCTs in the first 3 months. Donor type was not associated with differences in OS beyond 3 months after HCT, relapse, disease-free survival, or OS among patients who underwent HCT within 24 months of diagnosis. Patients who experienced graft failure had more advanced disease and commonly used nonmyeloablative conditioning. Although MSD-HCTs were superior, there is no significant difference in HCT outcomes from haploidentical and MUDs. These results establish haploidentical HCT with posttransplantation cyclophosphamide as a viable option in myelofibrosis, especially for ethnic minorities underrepresented in the donor registries.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Jain T, Estrada-Merly N, Salas MQ, et al. Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study. Blood Adv. 2024. PMID: 38916866. doi:10.1182/bloodadvances.2024013451

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。